Abstract: A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and NTRK3 have been reported in spitzoid melanocytic neoplasms leading to kinase-fusion proteins that result in immunohistochemically detectable ALK or NTRK expression. We have previously reported that ALK expression can be found in nonspitzoid primary and metastatic cutaneous melanomas. In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1, 1 involving NTRK2. They occurred in 3 women and 1 man. Two of the corresponding primary tumors were from the trunk, 1 from an extremity and 1 tumor arose in anal skin. One primary tumor displayed features of superficial spreading melanoma and 3 were nodular melanomas. All tumors were cytologically characterized by the presence of large epithelioid melanocytes. All tumors were immunoreactive with antiTrk antibody. Next-generation sequencing documented that the NTRK1 fusion partners included TRIM63, DDR2, and GON4L. One tumor harbored an NTRK2-TRAF2 fusion. Thus, our findings document that NTRK kinase fusions can occur in nonspitzoid metastasizing melanomas of adults. The presence of an NTRK family fusion in these tumors may provide a therapeutic opportunity in a small subset of patients with metastatic melanoma.
S everal driver mutations have been identified in melanoma. Four major mutation categories have been proposed for cutaneous melanoma: mutant BRAF, RAS, NF1, and triple wild-type tumors. 1 The latter group encompasses melanomas with molecular aberrations that are infrequent, such as mutations of KIT, 2,3 GNA11, 4 and GNAQ, 4 or genomic rearrangements of BRAF 5, 6 and RAF1. 7 Aside from mutations, the pathogenesis of melanoma is also influenced by other events, including, but not limited to DNA copy number changes, [8] [9] [10] [11] translocations, [12] [13] [14] [15] DNA methylation, 16 and alternative transcriptional initiation (ATI). 17 With regard to genomic rearrangements in melanocytic tumors, much has been learned from the study of spitzoid neoplasms. 10, 18 The most common type of aberrations in this subclass of melanocytic tumors involve various receptor-tyrosine kinases, including anaplastic lymphoma kinase (ALK), ROS1, neurotrophic tropomyosin receptor kinase 1 (NTRK1), NTRK3, RET, or MET, and the serine-threonine kinases BRAF. 12, 19, 20 The rearrangements link the kinase domain of these signaling proteins to a wide range of fusion partners, leading to highly expressed and kinase-active proteins. The resulting chimeric proteins stimulate multiple oncogenic signaling pathways and promote tumor initiation and progression. 12 Recent searches for possible similar genomic rearrangements in melanomas led to the discovery of a novel ALK isoform. 17 This transcript is expressed from a de novo ATI site in ALK intron 19, and was accordingly named ALK ATI . Melanomas with ALK ATI expression show positive staining by ALK immunohistochemistry (IHC). 17 In a large set of primary and metastatic melanomas ALK immunoreactivity was found only rarely, and if present, was not associated with ALK translocations, but with the truncated ALK ATI isoform. 21 Nonetheless, for the few patients whose tumors express ALK, it may provide a unique therapeutic opportunity.
In this study we sought to determine the frequency of NTRK gene rearrangements in metastasizing melanomas as this would also provide an option for targeted therapy, if the tumor did not respond to immunotherapy or other available treatments.
MATERIALS AND METHODS

Case Selection
The institutional data set (MSK BioPortal) was searched for cases of melanoma, which had been analyzed by MSK-IMPACT for treatment purposes. 22 Seven hundred fifty-one cases were identified, including melanomas of cutaneous (449 total, 395 nonacral, 54 acral), mucosal/ paramucosal (113), uveal (70), and primary CNS (2) origin, as well as metastases with unknown primary site (117). Of the 751 lesions, 3 metastatic melanomas of cutaneous origin and 1 metastasis from an anal primary melanoma were found with NTRK fusions.
The corresponding histopathologic material was retrieved and reviewed, including the metastatic lesions, which were subjected to sequence analysis, and the respective primary melanomas.
IHC Analysis
Five-micrometer-thick tissue sections were cut from tissue blocks. All 4 metastatic lesions were examined and 2 primary tumors, from which tissue was available.
A commercially available anti-TRK rabbit monoclonal antibody (clone EP1058Y; Abcam, Cambridge, MA) was used for IHC expression analysis of NTRK. The IHC assays were performed on a Leica-Bond-3 (Leica, Buffalo Grove, IL) automated stainer platform. The staining extent and pattern was recorded for each tumor.
Next-generation Sequencing
Next-generation sequencing (NGS) analysis was carried out within the context of an Institutional Review Board, approved protocol using MSK-IMPACT (NCT01775072), a deep-coverage hybridization capture-based assay encompassing 410 cancer-associated genes. MSK-IMPACT can detect missense mutations, indels, copy number alterations, and select gene fusions. 22 Analysis of tumor and normal (typically from blood) DNA was carried out to allow for accurate somatic mutation calling.
RESULTS
Clinical Findings
Four patients with metastatic melanomas harboring NTRK rearrangements were identified of 751 melanoma lesions for which NGS analysis (MSK-IMPACT) was available. They included 3 women and 1 man, in a range of 36 to 63 years of age (Table 1) .
Pathologic Findings
All 4 metastatic tumors with documented NTRK gene fusions (Table 1) were amelanotic and displayed epithelioid cell features (Figs. 1, 2) . The metastatic sites included lymph nodes, skin, colon, and duodenum. All metastatic tumors were immunoreactive for NTRK. No immunoreactivity for NTRK was found in a separate analysis of 20 lesions of metastatic melanoma lacking NTRK rearrangement.
Of the primary melanomas, 2 tumors were from the trunk, 1 from the lower extremity, and 1 arose in perianal skin. The latter showed features of superficial spreading melanoma, with an in situ component displaying intraepithelial pagetoid spread (Fig. 3) . The 3 other tumors were primary nodular melanomas (Table 1 and Fig. 4) . Tumor thickness ranged from 2.3 to 6.2 mm (mean, 4 mm; median, 3.7 mm). The tumor mitotic rates ranged from 4 to 27 mitoses/mm 2 ( Table 1) . Three melanomas were amelanotic. One tumor was focally pigmented. One tumor was ulcerated. The tumors were predominantly composed of epithelioid melanocytes (Figs. 3, 4) . Tissue material for IHC was available for 2 of the primary tumors. They were immunoreactive for NTRK. Positive staining was seen in both the in situ and invasive component (Fig. 4) .
Sequence Analysis
MSK-IMPACT identified the presence of NTRK fusion and partners. For NTRK1, the partners included Tripartite Motif Containing 63 (TRIM63), discoidin domain tyrosine kinase 2 (DDR2), and GON4L. NTRK2 was fused to TNF receptor-associated factor 2 (TRAF2) ( Table 1) . In 2 cases, the kinase fusions were found coexisting with known melanoma driver mutations, including an NF1 mutation (case 3) and NRAS Q61L mutation (case 4). Two tumors (cases 1 and 2) lacked a known driver mutation.
DISCUSSION
Although early-stage primary cutaneous melanoma is surgically curable, the prognosis is less favorable for patients with regional metastasis, and survival has historically been poor for patients with distant metastatic disease. 23 However, recent advances in immunotherapy and the development of selective kinase inhibitors [24] [25] [26] [27] [28] [29] have provided new opportunities for treatment of patients with advanced metastatic melanoma. Patients whose tumors harbor activating BRAFV600 mutations achieve improved overall survival and durable responses. 30, 31 Tumors with NRAS 32 and KIT 2,33-35 alterations have been targeted with more modest success.
While mutations of BRAF, NRAS, and NF1 are the most common alterations in melanoma, 1 a number of less common genomic aberrations have been identified, which might also provide new therapeutic opportunities. 19, 36 The identification of new targets continues to increase therapeutic options for cancer patients. 37 We have recently found a new isoform of the ALK receptor-tyrosine kinase in melanoma and other cancer types, and reported on a patient harboring this isoform who had transient clinical benefit to crizotinib. 17 In this study, we sought to determine the frequency of NTRK family rearrangement and expression in melanoma. Reviewing NGS data for melanomas of 751 patients, we found 4 metastatic lesions that harbored NTRK fusions. Three were derived from cutaneous primary tumors, 1 from a mucosal/paramucosal primary tumor.
On the basis of our cohort, the frequency of NTRK rearrangement in metastatic nonacral cutaneous melanoma is ∼0.8% (3/395) and 0.9% (1/113) in mucosal/paramucosal melanomas. This is lower than the previously found expression rate for ALK (2.3%) in a series of 603 melanomas. 21 However, in contrast to ALK expression in melanoma, which was related to the presence of an ALK isoform, NTRK expression was associated with the presence of a kinase fusion. Notably, 2 NTRK fusions co-occurred with other putative drivers (NF1 and NRAS). While this observation makes one consider that some melanomas may harbor multiple drivers, it is also possible that in context with a known driver mutation, the genetic alteration involving NTRK may not be critical for tumor growth and merely reflect a "passenger" aberration. Nonetheless, coexisting genetic abnormalities, whether at the intratumoral or intracellular level, may have implications for therapeutic efficacy of targeting a single driver alteration as previously observed in other tumors and implicated genes. [38] [39] [40] The presence of a fusion with placement of NTRK1 or NTRK2 downstream to a constitutively expressed promoter explains the homogenous expression of NTRK in melanomas, as detected by IHC. This lies in contrast to ALK, which tends to show heterogenous ALK immunoreactivity from focal and weak to strong and diffuse, likely related to epigenetic regulation of ALK ATI expression. While a prior IHC study used the pan-TRK antibody clone EPR17432 to document NTRK expression, 41 in this study we used the clone EP1058Y, because it produces more consistent and reliable results in our clinical laboratory.
NTRK comprises a family of tropomyosin receptor kinases. 42 Members include 3 transmembrane proteins referred to as Trk A, B, and C receptors. The corresponding genes are NTRK1, NTRK2, and NTRK3, respectively. These receptors play an important role in the development and function of neuronal tissue. 42 The NTRK1 gene is located on chromosome 1q21 to q22. 43 The NTRK2 gene is located on 9q21.33. Gene fusions represent the main molecular aberration involving NTRK in tumorigenesis, and have been found in various malignancies across different histologic phenotypes, including many different epithelial malignancies as well as glioblastomas, sarcomas, and so-called spitzoid melanomas. 12, [44] [45] [46] The type of NTRK fusions previously reported to be associated with spitzoid melanocytic neoplasms included LMNA-NTRK1 and TP53-NTRK1, 12 and ETV6-NTRK3, MYO5A-NTRK3, and MYH9-NTRK3. 13 The fusions found in this series included TRIM63-NTRK1, TRAF2-NTRK2, DDR2-NTRK1, and GON4L-NTRK1; all intrachromosomal rearrangements. The TRIM63 gene encodes for an E3 ubiquitin protein ligase 47, 48 that that mediates ubiquitination and proteasomal degradation of muscle proteins and that has been implicated in melanoma cell invasion. 49 The TRAF2 is involved in signal transduction from TNF receptors acting as a mediator of anti-apoptotic signals and activation of MAPK and NFkB. [50] [51] [52] The DDR2 encodes a collagen-induced receptor that activates pathways relevant to wound repair, tumor growth, and invasiveness. 53 The GON-4 like gene GON4L encodes a transcription factor associated with expression of CD24, a driver of progression and metastases in certain tumors. 54, 55 Although the role of the specific kinase fusions in the pathogenesis of melanoma and their impact on the phenotype is speculative and needs to be addressed by future studies; the promising responses seen to tyrosine kinase inhibitors in a wide variety of NTRK-rearranged tumors irrespective of histology and fusion partner, and the development of tyrosine kinase inhibitor-resistance through additional mutations on the kinase domain of the chimeric protein give testimony of NTRK's relevance in tumorigenesis and tumor survival. 56, 57 With regard to the histopathologic characteristics of the primary melanomas of this series, none of them displayed Spitz nevus-like features or was associated with a pre-existing nevus that had changed. Thus, our observations document that NTRK fusions in melanocytic neoplasms are not unique to Spitz tumors, and can also be found in association with adult-type nonspitzoid melanomas.
Most importantly, however, the fact that NTRK rearrangements and NTRK protein expression can be found in a small subset of cutaneous melanomas using NGS and IHC, has relevance for clinical care. Targeting NTRK and NTRK fusions represents a promising new opportunity for cancer treatment. 58, 59 Recently, the NTRK inhibitor larotrectinib demonstrated a 78% objective response rate in tumors with NTRK family fusions, regardless of histology. [58] [59] [60] [61] Given this efficacy, it would be worth testing the tumors of patients diagnosed with metastatic melanomas arising from cutaneous and paramucosal primary sites for NTRK fusions. IHC is an efficient way for screening for such NTRK kinase fusions. Thus, this provides another opportunity for pathologists to assist their clinical colleagues and patients in the search for personalized cancer treatment options.
